File Weekly Claim,
Amul Product Portfolio,
Tyler Ennis Basketball Number,
Sarah Ruhl Monologue,
Avant Credit Increase,
Valletta Malta Map,
App To Visualize Weight Loss,
Lipstick Queen Plumper Black,
Is Fiona Coming Back To Shameless Season 11,
Deborah Norville Mask Video,
Sunday Mail Puzzles,
Kroger Website Down 2020,
Tactical Medication Pouch,
Types Of Teaching Certificates,
Amazon Fire 10,
Bob Hayes 40 Time,
Sephora Contact Number,
Holby City Metro,
Is It Illegal To Sell Ebooks Online,
Canada Women's National Ice Hockey Team,
Isle Of Man Flag Vs Sicily,
Bell Mts Winnipeg,
Newcastle United Kit 2020-21,
Lynn Bowden Qb Highlights,
Imac (retina 5k 27-inch Late 2015) Ssd Upgrade,
Whole Foods Customer Satisfaction,
Nhl Uniform Changes,
Morganite Ring White Gold,
Ctv News Toronto Mobile,
Insecure Season 4 Episode 4 Review,
I Have A Date With Spring - Korean Movie Eng Sub,
Dylan Dreyer Net Worth,
Since joining Adverum in 2016, she has served as chief financial officer, and most recently as president, chief executive officer and director. Ms. Patterson earned a B.S.
Ms. Patterson has over 20 years of experience in the biotechnology industry. | Communications agency based in Vilnius, acting globally. Ms. Patterson currently serves on the board of directors for Nkarta, Inc. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. Adverum was formed after the merger of Avalanche Biotechnologies and Annapurna Therapeutics in May 2016. View Jean Chang’s professional profile on LinkedIn. in Business Administration and Accounting from Chapman University and an Executive M.B.A. from St. Mary’s College. Earlier, Ms. Patterson was vice president and chief financial officer of Transcept Pharmaceuticals, Inc. until it was acquired by Paratek Pharmaceuticals Inc. Adverum | 496 Follower auf LinkedIn | Strategic Communications, PR and Media Relations, Digital Marketing, Creative and Graphic design. Ms. Patterson has over 20 years of experience in the biotechnology industry. Since joining Adverum in 2016, she has served as chief financial officer, and most recently as president, chief executive officer and director. Earlier in her career, Ms. Patterson was vice president of finance at Exelixis, Inc. and vice president of global business planning and analysis at Novartis AG after the acquisition of Chiron. Adverum Biotechnologies, Inc. | LinkedIn‘de 2,575 takipçi | Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum Biotechnologies, formerly Avalanche Biotechnologies, is a gene therapy company. Adverum provides solutions to clients by implementing integrated and proactive communications strategies through strategic planning, public relations, media relations, crisis communications, … Previously, Ms. Patterson served as the chief financial officer of Diadexus, Inc. Adverum Biotechnologies, Inc. | 2,580 followers on LinkedIn | Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. Leone Patterson is Adverum’s president, leading key operational functions for the Company. Previously, Ms. Patterson served as vice president and global corporate controller of NetApp, Inc. Ms. Patterson is also a Certified Public Accountant (inactive status).